The Hottest IPOs of 2013
> First day increase: 53%
> Market cap: $1.12 billion
> Past two quarters revenue: $23.7 million
> Past two quarters income: -$10.0 million
Epizyme Inc. (NASDAQ: EPZM) is a clinical-stage biotech outfit targeting patients with genetically defined cancers. Since its public offering, the stock has done very well. Shares went public on May 31, with the IPO priced at $15 per share. The stock’s first trade was at $20.00, and shares continued to rise and ended up closing at $22.99, a 53.2% increase from the IPO price. Shares kept rising thereafter to a recent high of more than $45, before settling back down to just under $40 as of Friday’s close.
> First day increase: 54.6%
> Market cap: $2.21 billion
> Past two quarters revenue: $10.8 million
> Past two quarters income: -$43.2 million
Intrexon Corp. (NYSE: XON) has Exxon’s old stock ticker, and it could end up being one of the great companies of the future on its own merit. Intrexon uses synthetic biology to collaborate with companies in health, food, energy and the environment to create biologically based products. Initially, Intrexon intended to offer just 8.3 million shares. However, the offer size eventually was increased to 10 million shares and priced at $16 apiece — the peak of the expected range. In its first day, August 8, shares closed up more than 54% over the offering price, at $24.73. Shares then proceeded to trade up briefly over $30 in the two days after the IPO. However, shares are now back down to less than $25.
> First day increase: 56.8%
> Market cap: $1.39 billion
> Past two quarters revenue: $51.3 million
> Past two quarters income: -$2.0 million
Cvent Inc. (NYSE: CVT) has benefited from the success of its event planning platform, which helps exhibitors and event hosts alike. Its August 9 IPO was priced at $21.00 a share, and shares opened at $38.00 on their first day of trading. The stock closed down at $32.92 on the first day, but this still amounted to a gain of 56.8% over the offering price. Shares have traded with high levels of volatility since August, rising to a high above $46 on September 16. On Friday, shares closed at $34.70.
11. bluebird bio
> First day increase: 58.2%
> Market cap: $590.2 million
> Past two quarters revenue: $7.5 million
> Past two quarters income: -$11.1 million
bluebird bio Inc. (NASDAQ: BLUE) is a clinical-stage company targeting new gene therapies for severe genetic and rare diseases. It priced its IPO at $17.00 per share for trading on June 19, and shares opened higher at $25.50. Shares continued to rise and closed up 58.3% over the offering price at $26.91 on that first day. Shares soared to more than $36 at one point, but the stock has tumbled back to barely higher than its first-day opening price. Shares closed out Friday at $25.96.